A Phase 3, Multicenter, Randomized, Double-blind, AG-1749-controlled, Parallel-group, Comparison Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers during Long-term Therapy of Low-dose Aspirin.
Latest Information Update: 01 Nov 2018
At a glance
- Drugs Vonoprazan (Primary) ; Lansoprazole
- Indications Duodenal ulcer; Gastric ulcer
- Focus Registrational; Therapeutic Use
- Sponsors Takeda
- 07 May 2014 According to a Takeda media release, the results of this trial will be presented at the Digestive Disease Week 2014.
- 13 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 19 Oct 2011 New trial record